XERS vs. TARS, JANX, AGIO, NAMS, IDYA, SDGR, TVTX, BLTE, VERA, and IOVA
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Travere Therapeutics (TVTX), Belite Bio (BLTE), Vera Therapeutics (VERA), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.
Xeris Biopharma vs.
Xeris Biopharma (NASDAQ:XERS) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 3 mentions for Xeris Biopharma. Tarsus Pharmaceuticals' average media sentiment score of 0.87 beat Xeris Biopharma's score of 0.65 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.
Xeris Biopharma has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.
Xeris Biopharma has a net margin of -33.69% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Xeris Biopharma's return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.
Xeris Biopharma presently has a consensus target price of $5.15, indicating a potential upside of 37.15%. Tarsus Pharmaceuticals has a consensus target price of $56.00, indicating a potential upside of 17.28%. Given Xeris Biopharma's higher possible upside, equities research analysts plainly believe Xeris Biopharma is more favorable than Tarsus Pharmaceuticals.
42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Xeris Biopharma has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma received 96 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 69.90% of users gave Xeris Biopharma an outperform vote while only 66.67% of users gave Tarsus Pharmaceuticals an outperform vote.
Summary
Xeris Biopharma beats Tarsus Pharmaceuticals on 11 of the 19 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:XERS) was last updated on 2/22/2025 by MarketBeat.com Staff
